3 results match your criteria: "Unit of Digestive Disease of Campus Bio Medico University of Rome[Affiliation]"
Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the IG-IBD LIVE study.
Aliment Pharmacol Ther
July 2022
IBD Center, IRCCS Humanitas Research Hospital, Milan, Italy.
Background: Vedolizumab registration trials were the first to include elderly patients with moderate-to-severe ulcerative colitis (UC) or Crohn's disease (CD), but few real-life data have been reported in this population.
Aims: We investigated the effectiveness and safety of vedolizumab in matched cohorts of elderly and nonelderly UC and CD patients.
Methods: The Long-term Italian Vedolizumab Effectiveness (LIVE) study is a retrospective-prospective study including UC and CD patients who started vedolizumab from April 2016 to June 2017.
Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey.
Inflamm Bowel Dis
October 2020
IBD Center, Gastroenterology, Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy.
Background: Altered body composition is frequently observed in Crohn's disease (CD) patients.
Aims: To investigate the nutritional status, and the effect of different therapeutic regimes in adult CD patients.
Methods: Fat free mass (FFM) and BIA-derived phase angle (PhA) were assessed in 45 CD patients, 22 on conventional therapy (CT) and 23 on maintenance therapy with infliximab (MT).